LegalView Launches Viapro Drug Recall Site Due to Dangerous Ingredient Found in the Male Sexual-Enhancement Drug

Share Article

LegalView informed its readers of a recent drug recall of Viapro due to traces of an undeclared ingredient found in the product by the FDA. Viapro is a male sexual-enhancement drug used to treat erectile dysfunction.

LegalView, the number one resource for everything and anything legal on the Web, recently launched a new information portal informing readers of a drug recall that could cause serious side effects to its patients. Viapro, from EG Labs, was voluntarily recalled after representatives from the U.S. Food and Drug Administration (FDA) located trace amounts of an undeclared ingredient in the drug. The ingredient, thiomethisosildenafil, is an analog of sildenafil, which is the active chemical ingredient of Viapro, according to the FDA press release. Viapro is an over-the-counter medication, which claims to to treat erectile dysfunction (ED) among men in order to increase or enhance sexual abilities and performance.

The Viapro recall could severely affect individuals who may be taking other prescription drugs containing nitrates, such as nitroglycerin. Because the undeclared ingredient found in Viapro may interact negatively with nitrates, it is advisable for individuals who may be affected by this to seek medical attention immediately. Additionally, contacting an experienced pharmaceutical law firm that will be able to locate a Viapro attorney is advisable.

Patients taking Viapro and also consuming nitrates in drugs for diabetes, heart disease, high cholesterol or high blood pressure may be most at risk for the Viapro side effects, which can cause dangerously low levels of blood pressure. Contact a Viapro lawyer and learn about the potential for monetary compensation that can be awarded from a Viapro lawsuit.

Additionally, LegalView offers information on other various controversial pharmaceutical drugs and products including the latest on the Zimmer Durom cup failure, Ketek and Cipro.

Zimmer Holdings, a manufacturer of the Durom cup, recently ceased production of their hip socket product due to hundreds of complaints from physicians that the product was failing among patients who had received the Zimmer Durom cup. Since the product was introduced to the market in 2006, it has been implemented into more than 12,000 patients.

While Ketek and Cipro are both antibiotics treating similar infections, each has been under fire for posing serious risks to patients. Ketek, which treats upper respiratory infections such as pneumonia or bronchitis, has been linked to an increased risk of liver disease among patients. Individuals taking the drug who are showing signs of liver disease, including jaundice or yellowing of the skin, should seek medical attention immediately and discontinue consumption of the drug. Additionally, locating a pharmaceutical lawyer that has experience with Ketek class action lawsuits is encouraged.

Cipro, on the other hand, is an antibiotic that treats bacterial infections, similar to Ketek, but it has been linked to a very serious link of Achilles tendon rupture and tendonitis among patients. Cipro, which belongs to the fluoroquinolone drug family, recently had its labeling increased to a black-box warning along with the rest of the fluoroquinolone drugs. The black box labeling is the strongest label given by the FDA for a prescription drug and it often warns physicians about the serious Cipro risks associated with consuming the prescription antibiotic.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at http://www.LegalView.com/.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Kelley

Alan Haburchak
Visit website